MBIA reports $82 million unrealised loss mainly due to synthetic CDOs

New York-based monoline insurer MBIA said the largest negative impact on its income during 2002 arose from its synthetic collateralized debt obligation (CDO) investments. The majority of its total mark-to-market unrealised loss of $82 million was attributable to synthetic CDOs.

According to MBIA, $70 million of the unrealized loss occurred in the fourth quarter of 2002. The company claimed that approximately one-third of the total $82 million mark-to-market adjustment for last year resulted from the company's revised valuation methodology, and that the remaining two-thirds was attributable to a change in data source and wider spreads.

Though MBIA has ceased to write protection on single names, it had seven single-name investment grade corporate credit default swaps on its books last year. The notional outstandings of these vanilla trades was $276 million. The negative mark-to-market on this position was $4 million at the end of 2002. The company said that by the end of this year it will have just one vanilla position: a double-A rated single name net exposure of $41 million.

Speaking on MBIA’s earnings conference call earlier today, a company spokesman said: “Marking-to-market can provide useful information. But when you pass it through the income statement, it causes artificial distortions.” He added that he expects the mark-to-market value to become positive as the bulk of MBIA’s current synthetic positions reach maturity during the next three to four years.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here